Skip to Content

'
Mark R. Gilbert, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1982 The Johns Hopkins University, Baltimore, MD, MD, Medicine
1979 The Johns Hopkins University, Baltimore, MD, BA, Human Biology

Experience/Service

Other Appointments/Responsibilities

Co-Chair, Brain Tumor Committee, Radiation Therapy Oncology Group (RTOG), Philadelphia, PA, 4/2010-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Armstrong TS, Cao Y, Scheurer ME, Vera-Bolaños E, Manning R, Okcu MF, Bondy M, Zhou R, Gilbert MR. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol, 1/2010. PMID: 19179423.
2. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189-99, 9/2008. PMID: 18757334.
3. Armstrong TS, Gilbert MR. Use of complementary and alternative medical therapy by patients with primary brain tumors. Curr Neurol Neurosci Rep 8(3):264-8, 5/2008. PMID: 18541122.
4. Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev(2):CD004424, 2008. PMID: 18425902.
5. Gilbert MR, Armstrong TS. Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide. Ther Clin Risk Manag 3(6):1027-33, 12/2007. PMID: 18516257.
6. de Groot JF, Gilbert MR. New Molecular Targets in Malignant Gliomas. Curr Opin Neurol 20(6):712-8, 12/2007. PMID: 17992095.
7. Penas-Prado M, Gilbert MR. Molecularly Targeted Therapies for Malignant Gliomas: Advances and Challenges. Expert Rev Anticancer Ther 7(5):641-61, 5/2007. PMID: 17492929.
8. Gilbert MR, Lang FF. Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy? Nat Clin Pract Neurol 3:14-5, 1/2007. PMID: 17205067.
9. Armstrong T, Cohen MZ, Hess KR, Manning R, Lee EL, Tamayo G, Baumgartner K, Min SJ, Yung A, Gilbert M. Complementary and alternative medicine use and quality of life in patients with primary brain tumors. J Pain Symptom Manage 32:148-54, 8/2006. PMID: 16877182.
10. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM, Loeffler JS. Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms. Clinical Cancer Research 12/15:4738-46, 8/2006. PMID: 16899625.

Abstracts

1. Groves, MD, Tremont-Lukats IW, Conrad, CA, Cloughnessy T, Gilbert MR, Prados M, Schiff D, Yung, WKA. A phase II trial of temozolomide plus thalidomide (NABTC 99-04) for recurrent glioblastoma multiforme. Neuro-Oncol 4(1), 9/2002.
2. Colman, H, Hess KR, Turner MC, Puduvalli VK, Gilbert MR. Impact of Duration of Temozolomide Therapy on Progression-Free Survival in Recurrent Malignant Glioma. Neuro-Oncol 4(4):368, 2002.
3. Gilbert MR, Shono T, Lang FF. Role of p53 in the Resistance of Gliomas to Topoisomerase I Inhibition. Neuro-Oncol 4(4):322, 2002.
4. McDonald, JM, Fuller G, Goodman JC, Colman H, Gilbert M, Groves M, Tremont I, Zhang W, Aldape K. The Impact of Histology and 1p/19q Status on the Outcome of Patients with Anaplastic Oligodendroglioma (AO). Neuro-Oncol 4(4):344, 2002.
5. Conrad, C, Nakamizo A, Gumin J, Ji Y, Gilbert MR, Yung WKA, Lang FF. Using Glioma Xenograft Models for the Evaluation of Signal Transduction Inhibitors in Combination with Cytotoxic Chemotherapy: Survival, Pathologic and Molecular Correlates. Neuro-Oncol 4(4):322, 2002.
6. Armstrong TS, Gilbert MR. Evaluation of Quality of Life Indicators in Patients with Malignant Gliomas Undergoing Aggressive Treatment: A Pilot Study. Neuro-Oncol 7:337-338, 2001.

Last updated: 8/27/2013